



RECEIVED #6
JUN 12 2001
PATENT
Atty. Docket No. 1581000/2900
TECH CENTER 1000/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: William Manning, Jr. et al.

Serial No: 09/665,493 Group Art Unit: 1646

Filed: September 20, 2000 Examiner: to be assigned

Title: USE OF RECOMBINANT GENE DELIVERY VECTORS FOR
TREATING OR PREVENTING DISEASES OF THE EYE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 AND §1.97(b)(3)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The citations listed on the enclosed Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.

Items AA, AB, BB-BI, and CA-CH were submitted either in an Information Disclosure Statement and/or cited by the Examiner in related patent application Serial No. 09/525,956 from which the present application claims priority under 35 U.S.C. §120. Thus, pursuant to 37 C.F.R. §1.98(d), copies of the documents are not included.

Applicants have included a copy of the reference listed as Item BA on the Information Disclosure Statement PTO-1449 form.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class mail in an envelope addressed to: Assistant
Commissioner for Patents, Washington, D.C. 20231,
on this 4 day of June, 2001.
By [Signature]

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner is hereby authorized to charge any fees in connection with this Information Disclosure Statement to Deposit Account No. 03-1664.

Respectfully submitted,

By:



Anne S. Dollard
Attorney for Applicants
Reg. No. 43,935

May 30, 2001

CHIRON CORPORATION
Intellectual Property - R440
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-2719
(510) 655-3542 (fax)